Brachytherapy (Radioactive Seed Implantation Therapy) in Prostate Cancer Medication

1. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May. 103 (2):217-22. [QxMD MEDLINE Link].

2. Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012 Jan-Feb. 11(1):20-32. [QxMD MEDLINE Link].

3. Agency for Healthcare Research and Quality. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. AHRQ: Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9&DocID=79. Accessed: January 15, 2009.

4. Nag S. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations. Semin Urol Oncol. 2000 May. 18(2):133-6. [QxMD MEDLINE Link].

5. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan-Feb. 11(1):6-19. [QxMD MEDLINE Link].

6. Wattson DA, Chen MH, Moran BJ, et al. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012 Apr 1. 82 (5):e773-9. [QxMD MEDLINE Link].

7. Ishiyama H, Kamitani N, Kawamura H etal. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Brachytherapy. February 2017. 17:30012-20. [QxMD MEDLINE Link].

8. Shukla G1, Sarkar A2, Hanlon A3,. Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!. Brachytherapy. Feb 2017. 17:3003. [QxMD MEDLINE Link].

9. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar. 6(1):2-8. [QxMD MEDLINE Link].

10. B. R. Prestidge, K. Winter, M. G. Sanda, M. Amin et al. Initial Report of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma. Initial Report of NRG Oncology/RTOG 0232. 2016.

11. Koutrouvelis P, Hendricks F, Lailas N, Gil-Montero G, Sehn J, Khawand N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat. 2003 Aug. 2(4):339-44. [QxMD MEDLINE Link].

12. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999 Nov. 54(5):880-3. [QxMD MEDLINE Link].

13. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999 Jan. 53(1):2-10. [QxMD MEDLINE Link].

14. Petit JH, Gluck C, Kiger WS 3rd, Laury Henry D, Karasiewicz C, Talcott JA, et al. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy. 2007 Oct-Dec. 6(4):267-71. [QxMD MEDLINE Link].

15. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000 Jul 1. 89(1):135-41. [QxMD MEDLINE Link].

16. Kuban DA, el-Mahdi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 1992. 24(3):409-14. [QxMD MEDLINE Link].

17. Johnson K. Brachytherapy Benefits in High-Risk Prostate Cancer. Medscape Medical News. Available at http://www.medscape.com/viewarticle/843833#vp_2. April 28, 2015; Accessed: December 17, 2015.

18. Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology. 1998 Jun. 51(6):884-9; discussion 889-90. [QxMD MEDLINE Link].

19. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb. 109 Suppl 1:22-9. [QxMD MEDLINE Link].

20. Buchser D1, Gomez-Iturriaga A, Melcon JI, Casquero F, Llarena R, Cacicedo J, et al. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. Journal of contemporary brachytherapy. Dec 2016. 6:477-483. [QxMD MEDLINE Link].

21. Pons-Llanas O, Burgos-Burgos J, Roldan-Ortega S, et al. Salvage I-125 brachytherapy for locally-recurrent prostate cancer after radiotherapy. Rep Pract Oncol Radiother. 2020 Sep-Oct. 25 (5):754-9. [QxMD MEDLINE Link].

22. Baumann BC, Baumann JC, Christodouleas JP, Soffen E. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Brachytherapy. 2017 Mar - Apr. 16 (2):291-298. [QxMD MEDLINE Link].

23. Riaz N, Afaq A, Akin O, Pei X, Kollmeier MA, Cox B, et al. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Nov 1. 84(3):707-11. [QxMD MEDLINE Link].

24. Herstein A, Wallner K, Merrick G, Mitsuyama H, Armstrong J, True L, et al. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005 Sep-Oct. 11(5):385-9. [QxMD MEDLINE Link].

25. Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Jan 1. 64(1):136-43. [QxMD MEDLINE Link].

26. Cormack R. TU-FG-202-00: Advances and Innovations in Image Guided Brachytherapy. Medical physics. June 2016. 43(6):3759. [QxMD MEDLINE Link].

27. Langley SE, Laing RW. 4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds. BJU Int. 2012 Feb. 109 Suppl 1:1-6. [QxMD MEDLINE Link].

28. Nobes JP, Khaksar SJ, Hawkins MA, Cunningham MJ, Langley SE, Laing RW. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. Radiother Oncol. 2008 Jul. 88(1):121-6. [QxMD MEDLINE Link].

29. Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys. 2001 Jul 1. 50(3):597-604. [QxMD MEDLINE Link].

30. Steiner J, Matthews K, Jia G. WE-AB-BRA-11: Improved Imaging of Permanent Prostate Brachytherapy Seed Implants by Combining an Endorectal X-Ray Sensor with a CT Scanner. Medical physics. June 2016. 6:3793-3794. [QxMD MEDLINE Link].

31. Benzaquen D, Delouya G, Ménard C, Barkati M, Taussky D. Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherap. Brachytherapy. Jan 2017. 16:30645-6. [QxMD MEDLINE Link].

32. Urbanic JJ, Lee WR. Update on brachytherapy in localized prostate cancer: the importance of dosimetry. Curr Opin Urol. 2006 May. 16(3):157-61. [QxMD MEDLINE Link].

33. Ong WL, Matheson B, Millar J. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution. Brachyhterapy. Dec 2016. 16:30610-9. [QxMD MEDLINE Link].

34. Putora PM, Engeler D, Haile SR, Graf N, Buchauer K, Schmid HP, et al. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol. March 2016. 192 (3):182-9. [QxMD MEDLINE Link].

Lanna Cheuck, DO Director of Endourology, Montefiore Medical Center

Lanna Cheuck, DO is a member of the following medical societies: American Osteopathic Association, American Urological Association, Endourological Society, Society of Women in Urology

Disclosure: Nothing to disclose.

Charbel E Chalouhy, MD Fellow in Robotic and Laparoscopic Urologic Surgery, Department of Surgery, Albert Einstein College of Medicine

Charbel E Chalouhy, MD is a member of the following medical societies: American Society of Transplant Surgeons, American Urological Association, Endourological Society, Lebanese Order of Physicians

Disclosure: Nothing to disclose.

Edward David Kim, MD, FACS Professor of Urology, Department of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction, Tennessee Medical Association

Disclosure: Nothing to disclose.

Christopher S Atalla, DO Urologist, Good Samaritan Hospital Medical Center

Disclosure: Nothing to disclose.

Leester D Wu, MD Associate Director, Department of Radiation Oncology, South Nassau Communities Hospital

Leester D Wu, MD is a member of the following medical societies: American Society for Radiation Oncology, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Eric M Ghiraldi New York College of Osteopathic Medicine

Disclosure: Nothing to disclose.

Tracey L Krupski, MD, MPH Assistant Professor, Department of Urology, University of Virginia School of Medicine

Tracey L Krupski, MD, MPH is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Urological Association, and Society of Women in Urology

Disclosure: Nothing to disclose.

Daniel B Rukstalis, MD Director of Urological Services, Geisinger Medical Center, Geisinger Medical Group

Daniel B Rukstalis, MD is a member of the following medical societies: American Association for the Advancement of Science and American Urological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Dan Theodorescu, MD, PhD Paul A Bunn Professor of Cancer Research, Professor of Surgery and Pharmacology, Director, University of Colorado Comprehensive Cancer Center

Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology

Disclosure: Key Genomics Ownership interest Co-Founder-50% Stock Ownership; KromaTiD, Inc Stock Options Board membership

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article